CompletedPhase 2

A Biomarker Study of ATH434 in Participants With MSA

United States10 participantsStarted 2023-05-23

Plain-language summary

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Participant has clinical features of parkinsonism.
✓. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
✓. Participant has ataxia and/or pyramidal signs on neurological examination.
✓. Participant has biomarker evidence of MSA in biologic fluid and on MRI.

✕. Participant is unable to swallow study drug.
✕. Participant is unable to attend study visits or complete study procedures.
✕. Participant has structural brain abnormality on MRI.
✕. Participant has any significant neurological disorder other than MSA.
✕. Participant has an unstable medical or psychiatric illness.
✕. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.

Change in brain volume as measured by MRI

Timeframe: Change from Baseline to Week 52

NCT IDNCT05864365

SponsorAlterity Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-26